New! View global litigation for patent families

WO2008087642A3 - Nucleic acid constructs and methods for specific silencing of h19 - Google Patents

Nucleic acid constructs and methods for specific silencing of h19

Info

Publication number
WO2008087642A3
WO2008087642A3 PCT/IL2008/000072 IL2008000072W WO2008087642A3 WO 2008087642 A3 WO2008087642 A3 WO 2008087642A3 IL 2008000072 W IL2008000072 W IL 2008000072W WO 2008087642 A3 WO2008087642 A3 WO 2008087642A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
constructs
acid
sequence
methods
nucleic
Prior art date
Application number
PCT/IL2008/000072
Other languages
French (fr)
Other versions
WO2008087642A2 (en )
Inventor
Abraham Hochberg
Original Assignee
Yissum Res Dev Co
Abraham Hochberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.

Abstract

The present invention is directed to recombinant constructs and methods for treating pathological conditions associated with H19 expression, such as tumors characterized by up-regulated expression of H19 RNA. Specifically, the recombinant constructs of the invention comprise at least one nucleic acid sequence encoding a small interfering RNA (siRNA) molecule directed to H19, the nucleic acid sequence being operably linked to at least one H19-specific transcription-regulating sequence. Vectors comprising these constructs, pharmaceutical compositions comprising them and therapeutic methods of using same are also provided.
PCT/IL2008/000072 2007-01-16 2008-01-16 Nucleic acid constructs and methods for specific silencing of h19 WO2008087642A3 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US88043007 true 2007-01-16 2007-01-16
US88042507 true 2007-01-16 2007-01-16
US60/880,430 2007-01-16
US60/880,425 2007-01-16

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12523298 US20100086526A1 (en) 2007-01-16 2008-01-16 Nucleic acid constructs and methods for specific silencing of h19
CA 2675967 CA2675967A1 (en) 2007-01-16 2008-01-16 Nucleic acid constructs and methods for specific silencing of h19
EP20080702653 EP2111450A2 (en) 2007-01-16 2008-01-16 Nucleic acid constructs and methods for specific silencing of h19

Publications (2)

Publication Number Publication Date
WO2008087642A2 true WO2008087642A2 (en) 2008-07-24
WO2008087642A3 true true WO2008087642A3 (en) 2008-09-04

Family

ID=39434171

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IL2008/000072 WO2008087642A3 (en) 2007-01-16 2008-01-16 Nucleic acid constructs and methods for specific silencing of h19
PCT/IL2008/000071 WO2008087641A3 (en) 2007-01-16 2008-01-16 H19 silencing nucleic acid agents for treating rheumatoid arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/000071 WO2008087641A3 (en) 2007-01-16 2008-01-16 H19 silencing nucleic acid agents for treating rheumatoid arthritis

Country Status (4)

Country Link
US (2) US20100086526A1 (en)
EP (2) EP2111450A2 (en)
CA (2) CA2675964C (en)
WO (2) WO2008087642A3 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067573B2 (en) * 2005-07-07 2011-11-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19 and methods of using same
US20100178272A1 (en) 2006-08-08 2010-07-15 Klinische Pharmakologie Structure and use of 5'phosphate oligonucleotides
CA2675964C (en) * 2007-01-16 2015-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100196403A1 (en) * 2007-01-29 2010-08-05 Jacob Hochman Antibody conjugates for circumventing multi-drug resistance
EP2203187B1 (en) 2007-10-25 2012-08-29 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Constructs containing multiple expression cassettes for cancer therapy
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
JP2012515532A (en) 2009-01-20 2012-07-12 ラモット アット テル アビブ ユニバーシティ, リミテッド Mir-21 promoter-driven target cancer treatment
DE102010056610A1 (en) 2010-12-31 2012-07-05 Volker A. Erdmann A pharmaceutical composition comprising L-DNA
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
WO2016162807A1 (en) * 2015-04-10 2016-10-13 Universita' Degli Studi Di Palermo Microrna inhibitor for the treatment of aberrant angiogenesis and pathologies accompanied thereby
EP3291799A1 (en) 2015-05-05 2018-03-14 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Nucleic acid-cationic polymer compositions and methods of making and using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031359A2 (en) * 2002-10-03 2004-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for regulating expression genes

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
NL154598B (en) * 1970-11-10 1977-09-15 Organon Nv Method for the detection and determination of laagmoleculire compounds and of proteins that can specifically bind these compounds, as well as the test pack.
NL154599B (en) * 1970-12-28 1977-09-15 Organon Nv Method for the detection and determination of specific binding proteins and their corresponding bindable substances, as well as the test pack.
NL154600B (en) * 1971-02-10 1977-09-15 Organon Nv Method for the detection and determination of specific binding proteins and their corresponding bindable substances.
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) * 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) * 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) * 1972-05-11 1983-06-01 Akzo Nv Method for the detection and determination of haptens, as well as test packs.
US3850578A (en) * 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) * 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) * 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) * 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5011771A (en) * 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5550111A (en) * 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4666828A (en) * 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US5166315A (en) * 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) * 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5405938A (en) * 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4683202B1 (en) * 1985-03-28 1990-11-27 Cetus Corp
US4801531A (en) * 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE3751873D1 (en) 1986-04-09 1996-09-26 Genzyme Corp Genetically transformed animals that secrete a desired protein in milk
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5188897A (en) * 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
EP0406309A4 (en) * 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) * 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
CA2006008C (en) 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264562A (en) * 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5177198A (en) * 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587361A (en) * 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) * 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) * 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5677437A (en) * 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) * 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5618704A (en) * 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5608046A (en) * 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5541307A (en) * 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
DE69115702T2 (en) * 1990-08-03 1996-06-13 Sterling Winthrop Inc Compounds and methods for suppressing gene expression
US5177196A (en) * 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) * 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) * 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (en) * 1990-09-20 1994-06-30
US6933286B2 (en) * 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US20020123476A1 (en) * 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) * 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5571799A (en) * 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US6235887B1 (en) * 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5281521A (en) * 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5721138A (en) * 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
US5476925A (en) * 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) * 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
DE69407032T2 (en) * 1993-03-31 1998-07-02 Sanofi Sa Oligonucleotides having amide linkages employ phosphoesterverkettungen
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
EP0759092B1 (en) * 1994-03-07 2002-05-29 HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO. LTD. Cancer test comprising the use of a probe derived from the H19 gene
US5625050A (en) * 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6306559B1 (en) * 1999-01-26 2001-10-23 Mitsubishi Chemical Corporation Organic electroluminescent device comprising a patterned photosensitive composition and a method for producing same
WO2000071707A1 (en) 1999-05-20 2000-11-30 National Cancer Centre Of Singapore Pte Ltd A method for the diagnosis and treatment of cancer and agents useful therefor
US6303374B1 (en) * 2000-01-18 2001-10-16 Isis Pharmaceuticals Inc. Antisense modulation of caspase 3 expression
GB0001309D0 (en) * 2000-01-20 2000-03-08 Nestle Sa Valve arrangement
WO2002081628A8 (en) * 2001-04-05 2003-08-28 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
ES2215494T5 (en) * 2000-12-01 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Small RNA molecules that mediate RNA interference
US7552333B2 (en) * 2000-08-04 2009-06-23 First Data Corporation Trusted authentication digital signature (tads) system
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
EP1551856A2 (en) 2002-06-27 2005-07-13 Warner-Lambert Company LLC Novel therapeutic target for treating vascular diseases, dyslipidemias and related disorders
KR100774041B1 (en) * 2003-01-17 2007-11-06 유니버시티 오브 플로리다 리서치 파운데이션, 인크. Small interference rna gene therapy
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
JP5173793B2 (en) * 2005-04-29 2013-04-03 ザ ロックフェラー ユニバーシティ Micro rna and methods of inhibiting it
US8067573B2 (en) * 2005-07-07 2011-11-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19 and methods of using same
CA2675964C (en) * 2007-01-16 2015-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031359A2 (en) * 2002-10-03 2004-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for regulating expression genes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERTEAUX N ET AL: "H19 mRNA-like non-coding RNA promotes breast cancer cell proliferation through positive control by E2F1", JOURNAL OF BIOLOGICAL CHEMISTRY, AL, 28 June 2005 (2005-06-28), pages 1 - 24, XP002403575, ISSN: 0021-9258 *
LOTTIN S ET AL: "Thioredoxin post-transcriptional regulation by H19 provides a new function to mRNA-like non-coding RNA", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 21, 1 February 2002 (2002-02-01), pages 1625 - 1631, XP002981366, ISSN: 0950-9232 *
MATOUK IMAD ET AL: "Ablation of HCC by H19 knockdown", HEPATOLOGY, vol. 44, no. 4, Suppl. 1, October 2006 (2006-10-01), & 57TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVE R-DISEASES; BOSTON, MA, USA; OCTOBER 27 -31, 2006, pages 529A, XP009101101, ISSN: 0270-9139 *
STUHLMUELLER BRUNO ET AL: "Detection of oncofetal H19 RNA in rheumatoid arthritis synovial tissue.", AMERICAN JOURNAL OF PATHOLOGY, vol. 163, no. 3, September 2003 (2003-09-01), pages 901 - 911, XP002485007, ISSN: 0002-9440 *

Also Published As

Publication number Publication date Type
EP2111449A2 (en) 2009-10-28 application
WO2008087641A3 (en) 2008-09-04 application
WO2008087641A2 (en) 2008-07-24 application
CA2675967A1 (en) 2008-07-24 application
CA2675964C (en) 2015-12-22 grant
EP2111449B1 (en) 2012-03-07 grant
US20100086526A1 (en) 2010-04-08 application
CA2675964A1 (en) 2008-07-24 application
US20100105759A1 (en) 2010-04-29 application
US7928083B2 (en) 2011-04-19 grant
WO2008087642A2 (en) 2008-07-24 application
EP2111450A2 (en) 2009-10-28 application

Similar Documents

Publication Publication Date Title
WO2005014818A1 (en) Gene overexpressed in cancer
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008140615A3 (en) Modified messenger rna stabilizing sequences for expressing genes in bacterial cells
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2010041913A3 (en) Novel uses of grs proteins or fragments thereof
WO2004007718A3 (en) Rna-interference by single-stranded rna molecules
WO2010013815A1 (en) Composition for inhibiting expression of target gene
WO2003091440A1 (en) Method for constructing a linear expression vector without cloning
WO2005069762A3 (en) Bacillus licheniformis chromosome
WO2009143024A3 (en) Compounds and methods for kinase modulation, and indications therefor
WO2006053245A3 (en) Retroviral vectors with introns
WO2007142304A1 (en) SENSE OLIGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF iNOS AND COMPOSITION COMPRISING THE SAME
WO2004065600A3 (en) Rna interference by palindromic or modified rna molecules
WO2006120208A8 (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2005111217A3 (en) Nicotiana nucleic acid molecules and uses thereof
WO2005054438A3 (en) Nucleic acid molecules containing recombination sites and methods of using the same
WO2008106860A1 (en) Protein tyrosine phosphatase 1b inhibitor, preparation methods and uses thereof
WO2006066498A1 (en) The transcription factor gene osnacx from rice and use for improving tolerance of plants to drought and salt thereof
Scholz et al. Variation of the intercalating proline in artificial peptides mimicking the DNA binding and bending IHF protein
Luo et al. Synthesis of oligonucleotides with glucosamine at the 3′-position and evaluation of their biological activity
WO2007135685A3 (en) Compositions for silencing the expression of gibberellin 2-oxidase and uses thereof
WO2011022667A3 (en) Catalytic domains from lysyl oxidase and loxl2
WO2006116192A3 (en) Irta-1 antibodies and their uses
Yu et al. Development of universal primers for isolating fragments of the LEAFY gene

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08702653

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 199867

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2675967

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE